“Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)”

Bengt Rasmussen; Gudrun Göhring; Elsa Bernard; Lars Nilsson; Magnus Tobiasson; Martin Jädersten; Hege Garelius; Ingunn Dybedal; Kirsten Grønbaek; Elisabeth Ejerblad; Fryderyk Lorenz; Max Flogegård; Claus Werenberg Marcher; Annette Öster Fernström; Lucia Cavelier; Elli Papaemmanuil; Freja Ebeling; Astrid Olsnes Kittang; Jan Maxwell Nørgaard; Leonie Saft; Lars Möllgård; Eva Hellström-Lindberg

doi:10.1038/s41375-022-01537-w

“Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)”

Bengt Rasmussen, Gudrun Göhring, Elsa Bernard, Lars Nilsson, Magnus Tobiasson, Martin Jädersten, Hege Garelius, Ingunn Dybedal, Kirsten Grønbaek, Elisabeth Ejerblad, Fryderyk Lorenz, Max Flogegård, Claus Werenberg Marcher, Annette Öster Fernström, Lucia Cavelier, Elli Papaemmanuil, Freja Ebeling, Astrid Olsnes Kittang, Jan Maxwell Nørgaard, Leonie SaftLars Möllgård, Eva Hellström-Lindberg

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Original language	English
Pages (from-to)	1436-1439
Number of pages	4
Journal	Leukemia
Volume	36
Issue number	5
DOIs	https://doi.org/10.1038/s41375-022-01537-w
Publication status	Published - 1 May 2022
Externally published	Yes

Access to Document

10.1038/s41375-022-01537-w

Cite this

Rasmussen, B., Göhring, G., Bernard, E., Nilsson, L., Tobiasson, M., Jädersten, M., Garelius, H., Dybedal, I., Grønbaek, K., Ejerblad, E., Lorenz, F., Flogegård, M., Marcher, C. W., Öster Fernström, A., Cavelier, L., Papaemmanuil, E., Ebeling, F., Kittang, A. O., Nørgaard, J. M., ... Hellström-Lindberg, E. (2022). “Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)”. Leukemia, 36(5), 1436-1439. https://doi.org/10.1038/s41375-022-01537-w

@article{fd510c11e8d74d219f1af459900516ef,

title = "“Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)”",

author = "Bengt Rasmussen and Gudrun G{\"o}hring and Elsa Bernard and Lars Nilsson and Magnus Tobiasson and Martin J{\"a}dersten and Hege Garelius and Ingunn Dybedal and Kirsten Gr{\o}nbaek and Elisabeth Ejerblad and Fryderyk Lorenz and Max Flogeg{\aa}rd and Marcher, {Claus Werenberg} and {{\"O}ster Fernstr{\"o}m}, Annette and Lucia Cavelier and Elli Papaemmanuil and Freja Ebeling and Kittang, {Astrid Olsnes} and N{\o}rgaard, {Jan Maxwell} and Leonie Saft and Lars M{\"o}llg{\aa}rd and Eva Hellstr{\"o}m-Lindberg",

note = "Funding Information: Celgene for providing research grant and study drug. Swedish Cancer Society and Nordic Cancer Union for research grants. ",

year = "2022",

month = may,

day = "1",

doi = "10.1038/s41375-022-01537-w",

language = "English",

volume = "36",

pages = "1436--1439",

journal = "Leukemia",

issn = "0887-6924",

number = "5",

}

Rasmussen, B, Göhring, G, Bernard, E, Nilsson, L, Tobiasson, M, Jädersten, M, Garelius, H, Dybedal, I, Grønbaek, K, Ejerblad, E, Lorenz, F, Flogegård, M, Marcher, CW, Öster Fernström, A, Cavelier, L, Papaemmanuil, E, Ebeling, F, Kittang, AO, Nørgaard, JM, Saft, L, Möllgård, L & Hellström-Lindberg, E 2022, '“Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)”', Leukemia, vol. 36, no. 5, pp. 1436-1439. https://doi.org/10.1038/s41375-022-01537-w

TY - JOUR

T1 - “Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)”

AU - Rasmussen, Bengt

AU - Göhring, Gudrun

AU - Bernard, Elsa

AU - Nilsson, Lars

AU - Tobiasson, Magnus

AU - Jädersten, Martin

AU - Garelius, Hege

AU - Dybedal, Ingunn

AU - Grønbaek, Kirsten

AU - Ejerblad, Elisabeth

AU - Lorenz, Fryderyk

AU - Flogegård, Max

AU - Marcher, Claus Werenberg

AU - Öster Fernström, Annette

AU - Cavelier, Lucia

AU - Papaemmanuil, Elli

AU - Ebeling, Freja

AU - Kittang, Astrid Olsnes

AU - Nørgaard, Jan Maxwell

AU - Saft, Leonie

AU - Möllgård, Lars

AU - Hellström-Lindberg, Eva

N1 - Funding Information: Celgene for providing research grant and study drug. Swedish Cancer Society and Nordic Cancer Union for research grants.

PY - 2022/5/1

Y1 - 2022/5/1

UR - http://www.scopus.com/inward/record.url?scp=85126099436&partnerID=8YFLogxK

U2 - 10.1038/s41375-022-01537-w

DO - 10.1038/s41375-022-01537-w

M3 - Article

C2 - 35277655

AN - SCOPUS:85126099436

SN - 0887-6924

VL - 36

SP - 1436

EP - 1439

JO - Leukemia

JF - Leukemia

IS - 5

ER -

“Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)”

Access to Document

Other files and links

Cite this